Sign up for our daily briefing

Make your busy days simpler with the Axios AM and PM newsletters. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to the Axios Closer newsletter for insights into the day’s business news and trends and why they matter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with the Axios Sports newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with the Axios Des Moines newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with the Axios Tampa Bay newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

New data were released for Gilead's remdesivir. Photo: Justin Sullivan/Getty Images

Remdesivir, an antiviral drug made by Gilead Sciences, appears to help coronavirus patients recover more quickly than no treatment at all, but it does not significantly reduce death, according to preliminary data released today from the National Institutes of Health.

Yes, but: A conflicting trial in China, which also released full data today, said the opposite: That remdesivir doesn't appear to have a lot of clinical benefit.

Driving the news: The most reliable randomized studies — those where patients who get remdesivir, an antiviral IV medication, are contrasted with people who get a placebo — are finally starting to yield answers. But their contradictory conclusions are sowing more confusion.

The NIH study, a randomized trial of more than 1,000 people, showed hospitalized coronavirus patients who were on remdesivir got better four days faster than those who didn't get the drug (11 days vs. 15 days), but there was no statistically significant reduction in death.

  • The data, which are still undergoing peer review and weren't expected until May, show an "important proof of concept" for remdesivir but aren't necessarily a "knockout," the NIH's Anthony Fauci said at the White House today.
  • It's also worth noting people running the trial changed the primary outcome last month.

The Chinese study, a randomized trial of 237 patients that published in The Lancet (the same trial where a summary was leaked last week), said "remdesivir was not associated with statistically significant clinical benefits."

  • The problem: The smaller trial had to stop early because it ran out of patients to enroll.

The bottom line: The NIH study is the gold standard to watch right now, but leading experts ultimately agree the drug isn't something that will save the world from the coronavirus outbreak and at best likely offers limited help for people who get infected.

Go deeper

Updated Dec 8, 2020 - Health

The states where face coverings are mandatory

Data: Compiled by Axios; Map: Danielle Alberti/Axios

Wyoming on Monday became the latest state to implement a mask mandate to fight COVID-19, amid a steep spike in cases across the country.

The big picture: States are reintroducing mitigation efforts like closing businesses and advising people to stay home as the U.S. averages the most daily cases of any point in the pandemic.

Aug 7, 2020 - Health

Study finds COVID-19 antibodies prevalent in NYC health care workers

Photo: Noam Galai/Getty Images

More than 13% of health care workers in the greater New York City area tested positive for coronavirus antibodies, according to a newly published study.

Why it matters: The rate at which health care professionals tested positive for antibodies is consistent with the rate of COVID-19 antibodies found among randomly tested adults in the state of New York. The data released Thursday "is important so [health care workers] can protect themselves, their patients, their colleagues, and their families," per JAMA researchers.

Aug 6, 2020 - Health

HRW chief praises Apple, Google's contact tracing as privacy "gold standard"

Axios' Kim Hart and Kenneth Roth. Photo: Axios

The Bluetooth-based contact tracing system designed by Apple and Google is a current "gold standard" for prioritizing privacy when tracking the spread of the virus, Human Rights Watch executive director Kenneth Roth told Axios' Kim Hart at a virtual event Thursday.

Why it matters: Without a vaccine, promptly notifying those who have possibly been exposed to the coronavirus and encouraging self-quarantine is one of the best mitigation tools available.